



an Open Access Journal by MDPI

Multi-Omics in Cancers and Immune System

Guest Editors:

Dr. Jian He

The Center for Single-Cell Omics (CSCOmics), School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Dr. Vincent Vieillard

Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, 75013 Paris, France

Deadline for manuscript submissions:

closed (15 December 2023)

Message from the Guest Editors

Dear Colleagues,

This Research Topic aims to gather cutting-edge research that employs single-cell multi-omics techniques in the study of cancers and the immune system. We are seeking contributions that illuminate the molecular mechanisms underlying cancer progression, metastasis, and immune evasion. Additionally, we are interested in investigations into the diversity and functionality of immune cells within the tumor microenvironment, as well as unique insights into other diseases related to the immune system. Furthermore, we encourage research aimed at leveraging these high-resolution data to discover new biomarkers for early disease detection, diagnosis, prognosis, and treatment response.

The Research Topic contents mainly include, but are not limited to:

- Molecular mechanisms of cancer progression and metastasis through single-cell multi-omics
- Immune cell diversity and functionality within the tumor microenvironment
- Single-cell multi-omics insights into immune system-related diseases
- Biomarker discovery for early disease detection, prognosis, and treatment response



mdpi.com/si/179041



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)